Free Case Review

Qualify In Minutes

Submit Your Info Below

Dupixent Linked to Cutaneous T-Cell Lymphoma (CTCL) – You May Be Entitled to Compensation. Find out if you qualify for a free case review in minutes.

Bernstein Liebhard LLP is currently investigating reports of skin cancer, primarily CTCL or related subtypes, after using Dupixent. If you were diagnosed with skin cancer or your skin cancer worsened after Dupixent use, you may qualify for significant compensation. Contact our team today to see if you qualify for a complimentary case review – there’s no fee unless we obtain a recovery on your behalf.

We are currently reviewing claims for clients who developed the following cancers after taking Dupixent:

• Cutaneous T-Cell Lymphoma (CTCL)
• Mycosis Fungoides (MF)
• Sézary Syndrome (SS)
• Lymphomatoid Papulosis
• Subcutaneous Panniculitis-Like T-Cell Lymphoma
• Primary Cutaneous Anaplastic Large Cell Lymphoma
• Extranodal NK/T-Cell Lymphoma
• Primary Cutaneous Gamma/Delta T-Cell Lymphoma

To see if you qualify for compensation, please contact our office today at (866) 584-7477

By checking the box I expressly request and give permission to being contacted by Bernstein Liebhard LLP or their co-counsel practicing in this area of law, at any time, including but not limited to calls using an auto dialer, text, fax or email, in response to my inquiry at the telephone number(s) provided, even if these result in charges to me by my carrier. Consent is not a condition for services. This consent overrides any state, federal or corporate do-not-call registry rules or list.

Contact us today for a free, no-hassle, phone consultation. Learn about your options and let us answer your questions before you decide on a lawyer to represent you.

We have recovered over 3.5 billion dollars for our clients. However, if we don’t win you don’t pay any costs. 

Established in 1993, our firm has the knowledge/experience necessary to bring cases against big pharma and win. We take pride in driving quality results for each client.

Dupixent® (dupilumab) is a prescription drug widely marketed for eczema (atopic dermatitis), asthma, and other inflammatory conditions. While promoted as safe, growing reports and scientific concerns suggest Dupixent may be linked to serious, life-threatening skin cancers, including Cutaneous T-Cell Lymphoma (CTCL).

CTCL is a rare but aggressive form of non-Hodgkin’s lymphoma that begins in the skin. Patients have alleged that Regeneron and Sanofi, the makers of Dupixent, failed to adequately warn about these risks, potentially putting thousands of patients at risk.

Our firm is investigating claims nationwide for individuals who developed CTCL or related subtypes after using Dupixent.

• Nationally Recognized: Over 30 years of experience in complex litigation.
• Proven Success: Recovered over $3.5 billion for our clients.
• No Fees Unless You Win: We only get paid if we recover money for you.
• Personal Attention: Dedicated legal team guiding you every step of the way.

Our attorneys are trusted leaders in mass tort litigation, fighting for justice against some of the world’s largest pharmaceutical companies.

Victims and families may be entitled to recover damages for:

• Medical expenses (past & future)
• Lost wages & reduced earning capacity
• Pain & suffering
• Wrongful death (for families who lost a loved one)
• Punitive damages against manufacturers

Is Dupixent safe?

While Dupixent is FDA-approved, patients have reported developing rare but serious cancers, including CTCL. Lawsuits allege that the manufacturer failed to provide adequate warnings.

What if my cancer subtype isn’t listed?

Currently we are only investigating CTCL and the subtypes we have identified.

How much does it cost to hire your firm?

Nothing upfront. We work on a contingency basis – you pay nothing unless we win.

Free Case Review

Qualify In Minutes

Submit Your Info Above

Sandy A. Liebhard

Partner

Sandy A. Liebhard is a 1988 graduate of Brooklyn Law School and since that time he has been successfully representing plaintiffs in complex litigations. Mr. Liebhard served on the Plaintiffs’ Executive Committee in In re Initial Public Offering Securities Litigation ($586 million recovery) and was involved in the In re Fannie Mae Securities Litigation, where a $153 million settlement received final approval.

Daniel C. Burke

Partner

Daniel C. Burke earned his bachelor’s degree in 1990 from the State University of New York at Albany (B.A., English/History), and earned his J.D. in 1993 from St. John’s University School of Law, where he was a member of St. John’s Journal of Legal Commentary.

David R. Tawil

Counsel

David R. Tawil has over a decade of experience as part of the plaintiffs’ mass tort bar, including key roles in high profile complex litigation at both the trial and appellate levels. David has been recognized as a “Rising Star” by Super Lawyers since 2020 and has made Best Lawyers “Ones to Watch” lists in Plaintiffs’ Product Liability Litigation and Mass Tort/Class Actions since 2021.  

Ryan S. Sharp

Associate

Ryan S. Sharp received his bachelor’s degree in 2009 from SUNY Albany (Bachelor of Political Science). He received his J.D. in 2016 from Pace University School of Law. He was chosen to be part of the second inaugural class of the New York State Pro Bono Scholar Program in his last year at Pace University School of Law. Mr. Sharp has also been recognized as a “Rising Star” by Super Lawyers from 2018 to 2023.

RX Injury Help was established to connect readers with the tools they need to protect themselves from defective products and toxic exposures. The online resource guide created by the attorneys at Bernstein Liebhard LLP offers regularly updated information on dangerous drugs, defective medical devices, and hazardous substances, as well as relevant updates on the growing litigation of lawsuits involving such matters. If you or a loved one were harmed by Camp Lejeune’s contaminated water, our Firm will help you seek compensation for the damages incurred due to your exposure.

Attorney Advertising: Prior outcomes do not guarantee similar results.

Your use of our Web site or its facilities constitutes your acceptance of the Terms of Use and Privacy Policy.

Copyright © 2025

Bernstein Liebhard LLP

10 East 40th Street

New York, NY 10016

Phone: (866) 584-7477

Do not stop taking a prescribed medication or using a medical device without first consulting with your doctor. Discontinuing use of a prescribed medication or device without your doctor’s advice can result in injury or death.

Satellite Office

1111 Lincoln Road

Suite 706

Miami Beach, FL 33139